Cantargia presented positive phase I clinical data with lead candidate CAN04 at ESMO
· The antibody CAN04 was well tolerated and 6 mg/kg is a safe dose · Effects on biomarkers and 5 of 13 evaluable patients achieved stable disease · 10 mg/kg currently investigated before start of phase IIa during Q4 2018 Cantargia AB (publ) today presented interim results from its clinical Phase I/II trial CANFOUR of lead candidate CAN04 (nidanilimab) in a poster presentation at the ESMO Congress 2018 in Munich, Germany. Data from 16 patients with advanced cancer treated with weekly infusions between 1 mg/kg and 6 mg/kg were presented.The poster presentation – with the title A